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Abstract 
Background: The neuroendocrine glycoprotein chromogranin A is a useful biomarker in humans for neuroendo‑
crine tumors and stress. Chromogranin A can be measured in both blood and saliva. The objective of this study was 
to investigate concentrations of and correlation between the chromogranin A epitopes catestatin and vasostatin 
in healthy dogs accustomed to the sample collection procedures. Blood and saliva samples were collected from 10 
research Beagle dogs twice daily for 5 consecutive days, and from 33 privately‑owned blood donor dogs in associa‑
tion with 50 different blood donation occasions. All dogs were familiar with sample collection procedures. During 
each sampling, stress behavior was scored by the same observer using a visual analog scale (VAS) and serum cortisol 
concentrations. Catestatin and vasostatin were analyzed using radioimmunoassays for dogs.
Results: The dogs showed minimal stress behavior during both saliva sampling and blood sampling as monitored by 
VAS scores and serum cortisol concentrations. Few and insufficient saliva volumes were obtained and therefore only 
catestatin could be analyzed. Catestatin concentrations differed significantly and did not correlate significantly with 
vasostatin concentrations (P < 0.0001). Age, gender, breed, and time of sample collection did not significantly affect 
concentrations of plasma catestatin, vasostatin, and saliva catestatin.
Conclusions: The normal ranges of plasma catestatin (0.53–0.98 nmol/l), vasostatin (0.11–1.30 nmol/l), and saliva cat‑
estatin (0.31–1.03 nmol/l) concentrations in healthy dogs accustomed to the sampling procedures were determined. 
Separate interpretation of the different chromogranin A epitopes from either saliva or plasma is recommended.
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Background
Chromogranin A (CgA) is a biomarker that is widely used 
in human medicine, but few studies of CgA have been 
reported in dogs [1–6]. Chromogranin A, an acidic gly-
coprotein that belongs to the Granin family, is stored in 
chromaffin granules and coreleased with catecholamines 
and neuroendocrine hormones from the adrenal medulla 
and sympathetic nerve endings when the sympathoad-
renal-medullary system is activated [7, 8]. An active 
secretion of CgA into saliva in the submandibular gland 
has been found in humans [9], horses, and rats [10, 11]. 
Chromogranin A can be measured in saliva and blood in 
humans, pigs, cows, and dogs [4, 12–15]. Several bioac-
tive peptides are derived from CgA degradation, includ-
ing vasostatin, pancreastatin, catestatin, and serpinin 
[16–33]. These CgA bioactive peptides play different 
critical roles in the endocrine, cardiovascular, neurologic, 
and immune systems [21, 31, 34–36].
Chromogranin A is a reliable biomarker for diagnos-
ing and monitoring treatment outcome and prognosis in 
humans suffering from neuroendocrine tumors [8, 37–39]. 
Chromogranin A has detected in the myocardium in sev-
eral species and has multiple roles in cardiovascular home-
ostasis [40–42]. Chromogranin A and its derived peptides 
have shown promise as biomarkers for cardiovascular 
diseases such as hypertension, heart failure, myocardial 
infarction, and coronary syndromes [43–47]. Moreover, 
saliva CgA has been shown to be a sensitive biomarker for 
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stress in humans and pigs [12, 14, 48–53]. Some evidence 
suggests that CgA could be useful as a biomarker for neu-
roendocrine tumors and stress also in dogs [1, 2].
In humans, saliva sampling is preferable to blood 
sampling for monitoring stress because the technique 
is noninvasive [54, 55] and humans can be informed of 
the procedure and deliver saliva samples by voluntary 
spitting into a container. To obtain spontaneous saliva 
samples in dogs, however, collection swabs must be 
intraorally placed. Although noninvasive, the saliva sam-
ple collection procedure itself may cause a stress reac-
tion in dogs [56, 57]. To date, the stress response to saliva 
sampling in comparison with the stress response to blood 
sampling has not been evaluated in dogs. Stress evalua-
tion can be performed by subjective and objective meas-
urements, for example, scoring stress behavior using 
visual analog scale (VAS) scoring and measuring cortisol 
concentrations [58, 59].
Even though there are interspecies differences in CgA 
amino acid sequences, CgA can be measured in dogs [4]. 
A study on cross-reactivity between humans and dogs 
against different regions of the CgA molecule showed that 
CgA 17–38 (vasostatin) and CgA 361–372 (catestatin) 
could be measured using competitive radioimmunoassay 
(RIA) in dogs, whereas intact CgA could not [4]. Catestatin 
(CST) and vasostatin (VS), both CgA derived peptides, are 
bioactive. CST modulates catecholamine secretion (nega-
tive feedback) and has antihypertensive, antimicrobial, and 
cardiosuppressive effects [21, 22, 36, 60–63]. VS regulates 
plasma calcium, influences vasodilation, and has antimi-
crobial, and cardiosuppressive effects [17, 35, 42, 64–66]. 
Fundamental information concerning concentrations of 
CST and VS in healthy dogs of various breeds and gender 
that are accustomed to the sampling procedures is, how-
ever, lacking. The aims of this study were to investigate 
and compare concentrations of CST and VS in healthy 
dogs familiar with the collection procedures. In addition, 
we hypothesized that if CST and VS have similar halflives 
then the concentrations should not differ significantly.
Methods
Study design and ethical approval
This study was designed as a prospective clinical study in 
two parts; part one included destination bred research 
dogs, and part two included privately owned dogs admit-
ted for routine blood donation. The study was approved 
by the Uppsala Ethical Committee (C301/12) and all dog 
owners were informed and gave their consent prior to 
participation, in accordance with Swedish legislation.
Part one: research dogs
Three male and seven female research Beagle dogs (4–10 
years old) were included. All dogs were determined as 
healthy by complete physical examination including men-
tal status, general attitude, appetite, mucus membrane 
appearance, capillary refill time, rectal temperature, body 
weight, body condition score, hydration status, ausculta-
tion of heart and respiratory rate and sounds, abdominal 
palpation, and musculoskeletal system palpation. Dogs 
were familiar with being handled and routinely partici-
pated in practical teaching in the veterinary education 
program and were housed at the Research Animal Facil-
ity, Department of Clinical Sciences, Swedish University 
of Agricultural Sciences (SLU), Uppsala, Sweden.
Sampling of saliva and blood
Saliva and blood samples were collected twice daily for 
5 consecutive days at the following times: (A) 6:30–
7:30 am and (B) 1:00–2:00 pm, this time points were 
selected based on the results from previous pilot study 
[67, 68]. Saliva samples were collected using a swab size 
10 × 30 mm (SalivaBio, Salimetrics, PA, USA) placed in 
the oral cavity for 1 min. The swab was then transferred 
into a 4.5-ml polypropylene cryotube (CryoPure Tubes, 
Sarstedt, Nümbrecht, Germany) and centrifuged at 
3000 rpm (1401 g) for 15 min. The saliva deposited was 
stored at −70 °C until analysis of all samples.
Two ml of blood was collected from the distal cephalic 
vein using butterfly needles (BD Vacutainer, Becton-
Dickson, Plymouth, United Kingdom) into lithium hep-
arin tubes and clot activator tubes (Vacuette, Greiner 
Bio-One, Kremsmünster, Austria) and centrifuged at 
3300  rpm (1695 g) for 5 min. The obtained heparinized 
plasma samples were freeze stored in cryotubes (Low 
Temperature Freezer Vials, VWR, Stockholm, Sweden) at 
−70  °C until analysis of all samples within a maximum 
of 11 months storage time. The saliva sampling was per-
formed within 5 min prior to blood sampling.
Visual analog scale (VAS)
Visual analog scale scoring was performed during each 
saliva and plasma sampling occasion to score the sub-
jective stress behavior on a plain 100-mm line. The 
pre-established subjective criteria used in this study to 
determine stress behaviors during saliva and blood sam-
pling are given in Table 1 [69]. All sampling procedures 
were performed by the same two veterinarians and the 
sampling stress behavior VAS scores determined by one 
observer (TS).
Part two: blood donor dogs and donation routines
In total, thirty-three privately-owned dogs, twenty-four 
males and nine females, aged from one to eight years, of 
fourteen different breeds (Boxer, Bernese Mountain Dog, 
Collie, Dalmatian, Flat Coated Retriever, German Shep-
herd Dog, Golden Retriever, Great Dane, Greyhound, 
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Labrador Retriever, Leonberger, Shorthaired Pointer, 
White Shepherd, and Mixed Breed), were included in 
the study. All dogs that routinely donated blood at the 
University Animal Hospital (UDS), SLU, Uppsala, Swe-
den during April 2014, and from September to Febru-
ary 2015 were included. All dogs underwent a complete 
physical examination (as used for the research dogs) and 
blood samples were obtained from the distal cephalic 
vein and evaluated for health control purposes. Hema-
tology and biochemistry (creatinine, alanine ami-
notransferase (ALT), alkaline phosphatase (ALP), total 
protein, and albumin) were measured using in-house 
equipment (IDEXX ProCyte Dx and IDEXX Catalyst 
Dx, IDEXX Laboratories, Maine, USA). In all dogs, posi-
tive and negative DEA 1.1 blood type (Quick Vet, Scan-
dinavian Micro Biodevices ApS, Farum, Denmark) and 
presence of vector borne diseases including Anaplasma 
phagocytophilum, Anaplasma platys, Borrelia burgdor-
feri, Ehrlichia canis, Ehrlichia ewingii, and Dirofilaria 
immitis (Snap 4DX tests, IDEXX Laboratories, Maine, 
USA) were determined. Dogs with antibodies against 
Anaplasma phagocytophilum, Anaplasma platys, Bor-
relia burgdorferi, Ehrlichia canis, and Ehrlichia ewingii 
were considered healthy if no signs of active infection 
was present when examined, whereas dogs with positive 
antigens of Dirofilaria immitis were considered infected. 
Only healthy dogs were allowed to donate blood, and 
were enrolled for routine donation every 3–4 months. 
All dogs included in the present study were familiar with 
the sampling procedures and needed no sedation dur-
ing collection. Dog owners were present throughout 
procedures.
Sampling of saliva and blood
Heparinized plasma and serum samples remaining after 
the routine hematology and biochemistry analysis were 
used for the study. In total, seventeen dogs donated blood 
on one occasion whereas fifteen donated twice and one 
donated three times on different occasions (more than 3 
months interval) resulting in fifty separate samplings. All 
blood samples were collected by the same two certified 
veterinary nurses. Saliva sampling was performed by TS 
using the same criteria as in research dogs. In contrast 
to the sampling in research dogs, for practical reasons, 
blood and saliva sampling was performed on variable 
times between 8:00 am–2:00 pm, and the order in which 
the samples were collected was randomized with an 
interval between saliva and blood sampling of less than 
10 min. All samples were handled and stored in the same 
manner as described for research dogs.
Visual analog scale (VAS)
Visual analog scale scoring was performed by TS using 
the same criteria as in research dogs.
Table 1 Pre-established subjective criteria used to determine stress behaviors using visual analog scale
This stress behavior criteria are modified from Norling et al. [69]
Stress intensity No stress Mild stress Moderate stress Severe stress
A. Criteria used for saliva sampling






















Not able to sample
Not able to touch
Bites
Attacks
B. Criteria used for blood sampling
















Not able to sample
Not able to touch
Bites
Attacks
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Analysis of catestatin and vasostatin
Competitive radioimmunoassay (RIA) was used for 
measuring CST and VS. All heparinized plasma sam-
ples were analyzed in duplicates at  the Clinical Chem-
istry Laboratory, Uppsala University Hospital, Uppsala, 
Sweden as previously described [4, 70]. This method 
has been developed for both tissue and circulation and 
used for measuring CgA in humans. The detection limit 
is 0.01  nmol/l for plasma CST and VS and 0.04  nmol/l 
for saliva CST and the total coefficient of variance (CV) 
was <10%. The overall CV in the present study was <10%. 
For each analysis, 300 µl saliva and 100 µl plasma were 
required. The saliva sample volume obtained was insuf-
ficient for analysis of saliva VS.
Cortisol analysis
Serum samples were analyzed for cortisol concentrations 
in duplicate using a solid-phase competitive chemilumi-
nescent enzyme immunoassay (Immulite 2000, Siemens, 
Erlangen, Germany) at Clinical Chemistry Laboratory, 
UDS. The intraassay CV was <5%.
Statistical analysis
In all analysis of CST and VS, diagnostic plots were used 
to assess normality and homoscedasticity. Because the 
distributions of residuals for CST and VS data appeared 
skewed, these data were log transformed (natural log) 
prior to analysis. After transformation, no apparent devi-
ations from normality and homoscedasticity could be 
detected.
In all analysis, post hoc comparisons of least squares 
means were adjusted for multiplicity using Tukey’s 
method. Results were considered significant when 
P < 0.05. Most analysis were made using the mixed pro-
cedure of the SAS package 2014, but other procedures 
for basic statistics, Proc Univariate, Proc Corr and Proq 
Freq, were also used. Normal range was calculated using 
percentile 2.5–97.5 of log transformed data and back-
transformed to the original scale.
Research dog data
Because several measurements were made in each dog, 
mixed linear models [71, 72] were used for the analysis. 
The fixed part of the models included the variables “cat-
egory” with three levels (plasma CST, plasma VS, and 
saliva CST); day (1–5); gender (male or female); time of 
day (am or pm), and interactions between these factors. 
The random part of the model included dog, dog * day 
and dog * category.
The relations between the three measurements (catego-
ries) were modeled by allowing the R-side correlations 
among them to be an unstructured correlation matrix 
[71, 73]. This corresponds to using multivariate analysis 
of variance (MANOVA) model, but still allows for inclu-
sion of random effects in the model.
Blood donor dog data
For the blood donor dog data, the same categories as for 
the research dog data were used. Because the same dog 
could have data for one, two or three donation occasions, 
mixed models (ibid) were also used for these data.
Several models were tried. The fixed part of the mod-
els included category as above. Moreover, different back-
ground variables for the dogs (gender, age, and breed) 
and site (plasma and saliva) were tested. The R-side cor-
relations were modeled as for the research dogs. Random 
effects were dog, dog * site and dog * site * variable.
Comparisons between blood donor dogs and research dogs
The two data sets were collected in different ways. To 
allow comparisons between the groups, mean values 
were calculated, for all variables, for each dog. This led 
to a simple data set where comparisons between groups 
could be made using one-way ANOVA, or, equivalently, 
using two-sample t tests. These data sets were also used 
for calculating correlations between different variables.
Results
The mean ± SD age and body weight was 7.5 ± 2.6 years 
and 14.3 ±  1.2  kg in research dogs and 3.7 ±  2.0  years 
and 36.2 ± 9.8 kg in blood donor dogs. From the 50 blood 
donation occasions, 48 plasma and 40 saliva samples were 
obtained. Due to insufficient volumes remaining in some 
cases, plasma CST was analyzed in 39 of the 48 plasma 
samples, plasma VS in 44 of the 48 plasma samples and 
saliva CST in 40 of the 40 saliva samples. In the research 
dogs, plasma CST, plasma VS, and saliva CST could be 
analyzed in all samples collected (100). Mean ± SD values 
of serum cortisol were 39.9 ± 6.1 nmol/l in research dogs 
and 65.8 ± 28.2 nmol/l in blood donor dogs. Mean ± SD 
values of plasma CST, plasma VS, saliva CST, blood and 
saliva sampling stress behavior VAS scores from research 
and blood donor dogs are illustrated in Table 2. No sig-
nificant differences were found between research and 
blood donor dogs. The normal ranges of plasma CST, 
plasma VS, and saliva CST in this study was 0.53–0.98, 
0.11–1.30, and 0.31–1.03 nmol/l, respectively.
Plasma CST, plasma VS, and saliva CST concentra-
tions did not correlate significantly in any of the groups 
of dogs. In research dogs, plasma VS concentrations dif-
fered significantly from plasma and saliva CST concen-
trations (P  <  0.002). In blood donor dogs, plasma CST, 
VS, and saliva CST differed significantly (P  <  0.0001). 
Plasma CST, plasma VS, and saliva CST concentra-
tions did not differ significantly between different col-
lection times in research dogs. Plasma and saliva CST 
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concentrations did not differ significantly when com-
pared between different days of collection. Plasma CST, 
plasma VS, and saliva CST concentrations did not differ 
significantly between ages, genders, and breeds in both 
dog groups. Stress behavior VAS scores were low in all 
dogs and did not differ between sampling methods, ages, 
genders, breeds, collection time or day.
In the blood donor dogs, all hematology and blood 
chemistry results were deemed acceptable for blood 
donation. Nineteen dogs were positive for DEA 1.1 and 
14 negative for DEA 1.1. Plasma and saliva CST and VS 
did not differ significantly between blood groups. None 
of the blood donor dogs had positive antigens of Dirofi-
laria immitis. Six dogs had antibodies against Borrelia 
burgdorferi without clinical signs of disease. Plasma CST, 
VS, and saliva CST concentrations did not differ signifi-
cantly between positive and negative B. burgdorferi.
Discussion
This is the first study in dogs that investigates concen-
trations of and correlations between CST and VS in 
healthy dogs familiarized with a sample collection pro-
cedure. The concentration values and ranges reported 
here can be used as reference ranges for plasma CST, 
plasma VS, and saliva CST concentrations in healthy 
dogs when analyzed by RIA. Our findings will be use-
ful in future studies on the role and possibilities of using 
CST and VS as biomarkers in dogs. In a previous study 
of dogs with pyometra, using the same RIA as in the cur-
rent study, the reported serum CST concentrations in 
healthy control dogs were higher than reported here [5]. 
This difference between studies could be due to different 
familiarity to the handling techniques, and sample stor-
age time. Although CgA has been reported to be heat 
stable and the concentrations are stable through freeze 
and thaw cycle in humans and pigs [15, 74, 75], stud-
ies on CST and VS in dogs are lacking. In contrast to 
the previous study, the dogs included in our study were 
all well accustomed to the sampling procedures prior to 
sample collection, and showed minimal stress behaviors 
as monitored by stress behavior VAS scoring and serum 
cortisol concentrations [76].
Although both CST and VS are derived from CgA, the 
concentrations of plasma CST and VS in this study reflect 
both the intact CgA molecule and the two respective deg-
radation derived peptides. The significant differences in 
concentrations seen in the present study may be because 
the peptides have different functions and clearance rates. 
The CgA derived peptides might also be secreted differ-
ently into saliva and blood [13] which could contribute 
to our finding that CST concentrations were different in 
saliva and plasma in the blood donor dogs. Neverthe-
less, plasma CST, plasma VS, and saliva CST concentra-
tions did not correlate significantly in both dog groups. 
The concentrations of plasma CST, plasma VS, and saliva 
CST also did not vary by age, gender, or breed in either 
group of dogs. The results of the present study show 
that it is crucial to evaluate different CgA peptides indi-
vidually, and with regard to whether measurements were 
made in plasma or saliva because otherwise the results 
are not comparable.
Saliva sampling is preferable in humans because it is less 
invasive than blood sampling [54, 55]. In dogs, however, 
stress behaviors during saliva and blood sampling have 
not previously been evaluated and prolonged sampling 
time could induce stress [56, 57]. All dogs, in the pre-
sent study were well accustomed to the sampling proce-
dures and exhibit minimal stress levels as shown by stress 
behavior VAS scores and serum cortisol concentrations. 
However, in order to avoid inducing stress behavior we 
limited the time for saliva sampling to 60 s. We also chose 
not to pharmacologically induce saliva secretion because 
this may affect the secretion of neuroendocrine peptides. 
In the present study, there was no significant difference 
in the dogs’ acceptance of blood or saliva sampling as 
monitored by the stress behavior VAS. Our findings indi-
cate that saliva sampling is unpredictable and that for our 
research purposes, blood sampling is a better choice.
In human studies, saliva CgA has been used for evalu-
ating stress [12, 49–51]. In humans and pigs, active CgA 
Table 2 Mean ± SD of plasma catestatin, vasostatin, and saliva catestatin and sampling stress behavior score
In research dogs, plasma vasostatin concentrations differed significantly from plasma and saliva catestatin concentrations. In blood donor dogs, plasma catestatin, 
vasostatin, and saliva catestatin differed significantly. Blood and saliva sampling stress behavior VAS scores did not differ significantly between both dog groups
a,b,c Different letters within each column of concentration and stress behavior VAS score indicate significant differences using Tukey’s method adjustment (P < 0.05)
Parameters Research dogs (n = 10) Blood donor dogs (n = 33)
Plasma catestatin (nmol/l) 0.81 ± 0.08a 0.76 ± 0.10a
Plasma vasostatin (nmol/l) 0.57 ± 0.55b 0.44 ± 0.39b
Saliva catestatin (nmol/l) 0.83 ± 0.12a 0.64 ± 0.21c
Blood sampling stress behavior VAS score (mm) 8.9 ± 10.5a 19.1 ± 17.3a
Saliva sampling stress behavior VAS score (mm) 11.1 ± 7.8a 21.2 ± 16.7a
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secretion from the mandibular salivary gland has been 
found [9, 12, 14], however, little is known about CgA 
secretion in dogs. If similar active secretion also occurs 
in dogs, analysis of CST or VS in saliva may still be useful 
for monitoring stress levels. However, the sampling tech-
niques need to be improved to ensure sufficient sample 
volumes are obtained without undue stress or pharmaco-
logical intervention.
Ten research Beagle dogs were included in the study to 
investigate whether concentrations of CST and VS var-
ied over time in the same individual. In a previous pilot 
study, using the same RIA, five research Beagle dogs 
were sampled four times daily between 6:30 am and 
3:00 pm, saliva CST was increased in samples collected 
between 6:30 and 8:00 am [67, 68]. In addition, CgA in 
saliva has been found to be increased in early morning 
samples (7:00 am) in humans [13, 77, 78]. In our study, 
there was no significant difference in the concentrations 
of plasma CST, VS and saliva CST between time of day, 
which is in agreement with a previous study that used an 
ELISA for human CgA 344–374 amino acid sequence for 
saliva samples in dogs [3]. On the other hand, a circadian 
variation in CgA has been found in plasma and saliva in 
humans [13, 79]. However, as stated previously compari-
sons between different species and studies on different 
peptides should be made with caution.
The bioactive peptides of CgA have shown promise as 
prognostic and diagnostic biomarkers for neuroendo-
crine tumors, cardiac disease, burn trauma and stress 
in humans [12, 35, 80–82]. The main focus of this study 
was to investigate the concentrations of and correlation 
between CST and VS in healthy dogs familiar with the 
collection procedures. Further studies are warranted to 
investigate whether CST and VS can be used as biomark-
ers for neuroendocrine tumors, cardiovascular diseases, 
and stress in dogs.
Conclusions
Concentrations of plasma CST (0.53–0.98  nmol/l), 
plasma VS (0.11–1.30  nmol/l), and saliva CST (0.31–
1.03 nmol/l) in healthy dogs accustomed to the sampling 
procedures were determined. The concentrations of 
plasma CST, plasma VS, and saliva CST significantly dif-
fered and were unaffected by age, gender, breed, and time 
of sampling. No significant correlation between plasma 
CST and VS, as well as saliva CST could be found indi-
cating that separate interpretation of the different CgA 
epitopes from either saliva or plasma is mandatory.
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